2 recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 3 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Fatty Liver, Alcoholic: new trials by email Literature Review of Fatty Liver, Alcoholic trials Research Report on Fatty Liver, Alcoholic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD) Palm Tocotrienol Rich Fraction (TRF), Refined, bleached, and deodorised (RBD) palm olein - Alcoholic Fatty Liver Disease | Phase 2 | Not yet recruiting | Universiti Kebangsaan Malaysia Medical Centre | 26 | 2026-05-02 | 2026-04-29 |
| Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly | Not applicable | Recruiting | Phenomen Pharma | 90 | 2025-06-19 | 2025-07-23 |
| A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis Encapsulated FMT, Placebo - Liver Cirrhosis | Phase 3 | Recruiting | King's College London | 300 | 2023-06-21 | 2026-02-24 |
| Digoxin In Treatment of Alcohol Associated Hepatitis Intravenous digoxin - Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury | Phase 2 | Terminated | Yale University | 23 | 2021-10-08 | 2026-09-29 |
| Fatty Liver Disease Collaborative Research in China Fatty Liver, Fatty Liver, Alcoholic | Unknown | Fatty Liver and Alcoholic Liver Disease Study Group, China | 3000 | 2015-07-01 | 2015-08-05 | |
| Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Placebo /bid P.O, MG-1, MG-2 : MG1000mg, Placebo /bid P.O - Alcoholic Fatty Liver Disease, Alcoholic Hepatitis | Phase 2 | Completed | PharmaKing | 90 | 2010-11-01 | 2015-04-29 |
Liver Diseases (3) · Non-alcoholic Fatty Liver Disease (3) · Fatty Liver (2) · Alcohol-Induced Disorders (1) · Chemical and Drug Induced Liver Injury (1) · Fibrosis (1) · Hepatic Encephalopathy (1) · Hepatic Insufficiency (1) · Hepatitis (1) · Hepatitis, Alcoholic (1) · Hepatomegaly (1) · Infections (1) · Liver Cirrhosis (1)
Alcohol-Related Disorders (6) · Chemically-Induced Disorders (6) · Digestive System Diseases (6) · Liver Diseases, Alcoholic (6) · Substance-Related Disorders (6) · Alcohol-Induced Disorders (5) · Fatty Liver (4) · Liver Diseases (3) · Pathological Conditions, Signs and Symptoms (2) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Central Nervous System Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Hepatitis (1) · Hypertrophy (1)
Digoxin (1) · S-Adenosylmethionine (1) · Ursodeoxycholic Acid (1) · metadoxine (1)
Fatty Liver and Alcoholic Liver Disease Study Group, China (1) · King's College London (1) · PharmaKing (1) · Phenomen Pharma (1) · Universiti Kebangsaan Malaysia Medical Centre (1) · Yale University (1)
China (1) · Malaysia (1) · Russia (1) · South Korea (1) · United Kingdom (1) · United States (1)
Bubu Banini, MD, PhD (1) · Jiangao Fan, MD (1)